Skip to main content
Top

Current Treatment Options in Oncology

Issue 12/2016

Content (7 Articles)

Skin Cancer (BY Kwong, Section Editor)

Management of Skin Cancer in the High-Risk Patient

James W. Behan, Adam Sutton, Ashley Wysong

Skin Cancer (BY Kwong, Section Editor)

Drug Combinations as the New Standard for Melanoma Treatment

Marta Polkowska, Edyta Czepielewska, Małgorzata Kozłowska-Wojciechowska

Lung Cancer (HA Wakelee, Section Editor)

From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?

Ettore D’Argento, Sabrina Rossi, Giovanni Schinzari, Antonia Strippoli, Michele Basso, Alessandra Cassano, Carlo Barone

Genitourinary Cancers (W Oh and M Galsky, Section Editors)

Sequencing Treatment for Castration-Resistant Prostate Cancer

Catherine E. Handy, Emmanuel S. Antonarakis

Open Access Genitourinary Cancers (W Oh and M Galsky, Section Editors)

Oligometastatic Prostate Cancer

Daniel J. Stevens, Prasanna Sooriakumaran

Erratum

Erratum to: Cutaneous Complications of Targeted Melanoma Therapy

Emily de Golian, Bernice Y. Kwong, Susan M. Swetter, Silvina B. Pugliese

Erratum

Erratum to: From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?

Ettore D’Argento, Sabrina Rossi, Giovanni Schinzari, Antonia Strippoli, Michele Basso, Alessandra Cassano, Carlo Barone

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine